Profluent logo — Grounded in nature, authored by AI

Profluent

Grounded in nature, authored by AI

Founded 2022 United States Emeryville, United States 69 employees Venture round Total: $44.00M AI, Biotechnology

General Information

Company Name Profluent
Founded Year 2022
Location United States Emeryville, United States
Employees 69
Industries AI, Biotechnology
Funding Stage Venture round
Business Model B2B, Platform, API
Revenue Model Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Profluent. To contact Profluent, visit profluent.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Profluent compare?

A PDF of Profluent and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Profluent soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Major Customer Win Sep 30, 2026

Profluent has secured BioMarin as a major customer, who will utilize Profluent's AI models for the design of novel medicines.

About Profluent

Profluent, a pioneering player in the intersection of AI and biotechnology, is making significant strides in revolutionizing protein design. Established in 2022, the company is based in Emeryville, CA, and has garnered support from top-tier investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.

Positioned as an AI-first protein design entity, Profluent utilizes deep generative models to create and validate novel proteins, with a vision to revolutionize biomedicine. Their slogan, "Grounded in nature, authored by AI," embodies their mission to decode the language of life using advanced technology.

The company's latest financial milestone was a $35.00M Venture Round investment secured on 21 March 2024, further cementing its potential in the industry. Notably, investors like Jeff Dean have shown confidence in Profluent, affirming its innovative approach and growth prospects.

Business keywords: AI-first protein design, deep generative models, novel proteins, biomedicine revolution, functional protein design, protein validation, AI in biotech, gene editing, machine learning applications, biotech innovation, synthetic biology, life sciences, therapeutic protein development, biomedical research, computational biology

Services & Products

AI-authored Protein Solutions
CRISPR Gene Editing
Custom Protein Design
Biological Research and Development

Target Customers

Pharmaceutical Companies Agricultural Biotechnology Firms Industrial Biotech Manufacturers Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $35.00M 6
Air Street Capital, Insight Partners +4
21 Mar 2024
Seed Round $9.00M 4
Air Street Capital, Insight Partners +2
25 Aug 2022

Profluent Alternatives & Competitors

View All Alternatives
Profluent vs
Absci
Absci United States

Unlocking differentiated biology with generative AI

IPO
158 employees
AI, Biopharma
Profluent vs
Synthego
Synthego United States

Your Partner in CRISPR & Molecular Diagnostics

172 employees
AI, Automation
Profluent vs
Asimov
Asimov United States

Intelligent design of living systems

Series B
119 employees
AI, Biotechnology

FAQ About Profluent

Grounded in nature, authored by AI
Profluent was founded in 2022.
Profluent is headquartered in Emeryville, United States.
Profluent operates in AI and Biotechnology. Its work centres on AI-first protein design, deep generative models, novel proteins and biomedicine revolution. Its customers include Pharmaceutical Companies, Agricultural Biotechnology Firms and Industrial Biotech Manufacturers.
Profluent has a B2B, Platform and API business model. Its revenue comes from Licensing and Service Fee.
Profluent has approximately 69 employees.
Profluent has completed 2 funding rounds, raising a total of $44.00M. The latest funding stage is Venture round.
Profluent offers: AI-authored Protein Solutions, CRISPR Gene Editing, Custom Protein Design, Biological Research and Development.
Top alternatives and competitors to Profluent include Absci, Synthego, Asimov, Basecamp Research, AI Proteins. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Profluent and Absci are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Profluent, https://bouncewatch.com/company/profluent-bio, updated 25 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes